Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells

Molecular Cancer

Volumn 4, Issue , 2005, Pages

  Huang, Hosea F ^a   Murphy, Thomas F ^a   Shu, Ping ^a   Barton, Arnold B ^a   Barton, Beverly E ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTISENSE OLIGONUCLEOTIDE; GROWTH FACTOR; JANUS KINASE INHIBITOR; MESSENGER RNA; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; STAT3 PROTEIN; ALPHA CYANO (3,4 DIHYDROXY) N BENZYLCINNAMIDE; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; ANDROSTANOLONE; DNA BINDING PROTEIN; ENZYME INHIBITOR; GROWTH PROMOTOR; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, RAT; JANUS KINASE 2; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RETINOIC ACID RECEPTOR; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, RAT; TRANSACTIVATOR PROTEIN; TYRPHOSTIN;

AGAR MEDIUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; EXPRESSION VECTOR; GENETIC TRANSFECTION; HORMONE RESPONSE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PHENOTYPE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RAT; SCID MOUSE; ANIMAL; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; CYTOLOGY; DRUG ANTAGONISM; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; MALE; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR;

ANDROGENS; ANIMALS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DIHYDROTESTOSTERONE; DNA-BINDING PROTEINS; ENZYME INHIBITORS; EPITHELIAL CELLS; GENE EXPRESSION; GROWTH SUBSTANCES; HUMANS; JANUS KINASE 2; MALE; MUTATION; PHENOTYPE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RATS; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSFECTION; TYRPHOSTINS;

EID: 13644252492     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-4-2     Document Type: Article

References (54)

1. Ihle JN: STATs and MAPKs: obligate or opportunistic partners in signaling. BioEssays 1996, 18:95-98.
2. Aaronson DS, Horvath CM: A Road Map for Those Who Don't Know JAK-STAT. Science 2002, 296:1653-1655.
3. Schroder M, Kroeger KM, Volk HD, Eidne KA, G. G: Preassociation of nonactivated STAT3 molecules demonstrated in living cells using bioluminescence resonance energy transfer: a new model of STAT activation? J Leukoc Biol 2004, 75:792-797.
4. Kretzschmar AK, Dinger MC, Henze C, Brocke-Heidrich K, Horn F: Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells. Biochem J 2004, 377:289-297.
5. Sehgal PB: Plasma membrane rafts and chaperones in cytokine/STAT signaling. Acta Biochim Pol 2003, 50: 83-594.
6. Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8:945-954.
7. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitski A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
8. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran Jr. TP: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001, 107:351-362.
9. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zang Q, Pitt AS, Tweardy DJ: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998, 102:1385-1392.
10. Barton BE, Murphy TF, Adem P, Watson RA, Irwin RJ, Huang HS: IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer 2001, 1:19.
11. Barton BE, Karras JG, Murphy TF, Barton AB, Huang HF: STAT3 Activation in Prostate Cancer: Direct STAT3 Inhibition Induces Apoptosis in Prostate Cancer Lines. Mol Cancer Ther 2004, 3: 1-20.
12. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofen M, Barton AB: Novel Single-Stranded Oligonucleotides that Inhibit STAT3 Induce Apoptosis In Vitro and In Vivo in Prostate Cancer Cell Lines. Mol Cancer Ther 2004, 3:1183-1191.
13. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R: Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002, 62:6659-6666.
14. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE: Stat3 as an oncogene. Cell 1999, 98:295-3-3.
15. Bromberg J: Stat proteins and oncogenesis. J Clin Invest 2002, 109:1139-1142.
16. Brawer MK: Prostate cancer: where have we been, where we are, where we are going. World J Surg 2000, 24:1200-1204.
17. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin 1999, 49:8-31.
18. Jemal A, Thomas A, Murray T, Thun M: Cancer Statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
19. Albertsen PC: A cancer conundrum. N Engl J Med 2002, 347:930-931.
20. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, Van Der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, Van Dekken H: Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 2004, 13: 303-1313.
21. Milbank AJ, Dreicer R, Klein EA: Hormonal therapy for prostate cancer: primum non nocere. Urology 2002, 60: 38-741.
22. Denmeade SR, Lin XS, Isaacs JT: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996, 28:251-265.
23. Gao J, Arnold JT, Isaacs JT: Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001, 61:5038-5044.
24. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate 2000, 42:239-242.
25. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M: In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-1 receptor (IGF-IR). Cancer Res 2001, 61:6276-6280.
26. Chung TDK, Yu JJ, Spiotto MT, Bartkowski M, Simons JW: Characterization of the role of IL-6 in the progression of prostate cancer. The Prostate 1999, 38:199-207.
27. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH: Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003, 112:1724-1731.
28. Ueda T, Bruchovsky N, Sadar MD: Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002, 277:7076-7085.
29. Zhang J, Yang J, Roy SK, Tininini S, Hu J, Bromberg JF, Poli V, Stark GR, Kalvakolanu DV: The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci USA 2003, 100:9342-9347.
30. Kalvakolanu DV: The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Reviews 2004, 15:169-194.
31. Hu J, Angell JE, Zhang J, Ma X, Seo T, Raha A, Hayashi J, Choe J, Kalvakolanu DV: Characterization of monoclonal antibodies against GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res 2002, 22: 017-1026.
32. Keedwell RG, Zhao Y, Hammond LA, Qin S, Tsang KY, Reitmair A, Molina Y, Okawa Y, Atangan LI, Shurland DL, Wen K, Wallace DM, Bird R, Chandraratna RA, Brown G: A retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation. Cancer Res 2004, 64:3302-3312.
33. Wang Q, Wieder R: All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene 2004, 23:426-433.
34. Richter F, Huang HFS, Li MT, Danielpour D, Irwin RJ: Retinoid and androgen regulation of cell growth, epidermal growth factor and retinoic acid receptors in normal and carinoma at prostate cells. Mol Cell Endocrinol 1999, 153:29-38.
35. Richter F, Joyce A, Fromowitz F, Wang S, Watson JE, Watson R, Irwin RJJ, Huang HF: Immunohistochemical localization of the retinoic acid receptors in human prostate. J Androl 2002, 23: 30-838.
36. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB: Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 1994, 54:4313-3421.
37. Hayward SW, Haughney PC, Lopes ES, Danielpour D, Cunha GR: The rat prostatic epithelial line NRP-152 can differentiate in vivo in response to its stromal environment. Prostate 1999, 39: 05-212.
38. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR: Malignant transformation in a nontumorigenic prostatic epithelial cell line. Cancer Res 2001, 61: 135-8142.
39. Besser D, Bromberg JF, Darnell Jr. JE, Hanafusa H: A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol Cell Biol 1999, 19:1401-1409.
40. Shen Y, Devgan G, Darnell Jr. JE, Bromberg JF: Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA 2001, 98: 543-1548.
41. Danielpour D: Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-beta. J Cell Sci 1998, 112:169-179.
42. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM: A mechanism for androgen receptor-mediated prostate recurrence after androgen deprivation therapy. Cancer Res 2001, 61:4315-4319.
43. Zhang L, Johnson M, Le KH, Sato S, Ilagan R, Iyer M, Gambhir SS, Wu L, Carey M: Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 2003, 63:4552-4560.
44. Wieder R, Wang H, Shirke S, Wang Q, Menzel T, Feirt N, Jakubowski AA, Gabrilove JL: Low level expression of basic FGF upregulates Bcl-2 and delays apoptosis, but high intracellular levels are required to induce transformation in NIH 3T3 cells. Growth Factors 1997, 15:41-60.
45. Bromberg J, Darnell Jr. JE: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473.
46. Yang L, Lian X, Cowen A, Xu H, Du H, Yan C: Synergy between signal transducer and activator of transcription 3 and retinoic acid receptor-alpha in regulation of the surfactant protein B gene in the lung. Mol Endocrinol 2004, 18:1520-1532.
47. Matsuda T, Junicho A, Yamamoto T, Kishi H, Kormaz K, Saatcioglu F, Fuse H, Muraguchi A: Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 2001, 283:179-187.
48. Zhang YW, Wang LM, Jove R, Vande Woude GF: Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 2002, 21:217-226.
49. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23:3550-3560.
50. Joo A, Aburuatani H, Morii E, Iba H, Yoshimura A: STAT3 and MITF cooperatively induce cellular transformation through upregulation of c-fos expression. Oncogene 2004, 23: 26-734.
51. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg J: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 2004, 101:10602-10607.
52. Barton BE, Murphy TF: Constitutive expression of IL-6-like cytokines in normal bone marrow: Implications for myeloma pathophysiology. Cytokine 2000, 12:18-27.
53. Young IT: Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977, 25:935-941.
54. Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P: Use of antisense oligonucleotides targeting the anti-apoptotic gene, clusterin/testosterone-repressed message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 2001, 58(2 Suppl 1):39-49.